Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2020, with a specific reporting date of October 13, 2020. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares (Share Reward Plan) |
| Share Price | £14.3992 per share |
| Transaction Date | October 9, 2020 |
| Exchange | London Stock Exchange (XLON) |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It details routine compliance notifications for share acquisitions by senior executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific equity transactions.
Important Facts for Investors
- Insider Buying Activity: Multiple senior executives, including CEO Emma Walmsley, acquired shares on October 9, 2020, indicating participation in the company's Share Reward Plan.
- Transaction Volume: Individual transactions ranged from 16 to 18 shares per executive, consisting of partnership and matching shares.
- Share Price Reference: The transactions were executed at a uniform price of £14.3992.
- No Financial Data: Investors should not use this document for financial performance analysis; refer to Form 20-F or quarterly earnings releases for revenue and profit data.